A detailed history of Algert Global LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 126,730 shares of RVNC stock, worth $325,696. This represents 0.02% of its overall portfolio holdings.

Number of Shares
126,730
Previous 10,000 1167.3%
Holding current value
$325,696
Previous $26,000 2430.77%
% of portfolio
0.02%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.57 - $2.57 $299,996 - $299,996
116,730 Added 1167.3%
126,730 $658,000
Q2 2024

Aug 14, 2024

SELL
$2.34 - $4.73 $297,788 - $601,939
-127,260 Reduced 92.71%
10,000 $26,000
Q1 2024

May 14, 2024

SELL
$4.65 - $9.31 $31,527 - $63,121
-6,780 Reduced 4.71%
137,260 $675,000
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $836,872 - $1.61 Million
144,040 New
144,040 $1.27 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.